GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Isavuconazonium sulfate (Cresemba)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug7 sources available - open source summaries, references and comparisons

Cresemba / Isavuconazole

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (7)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Cresemba - product and source limitations

Hemodialysis does not remove isavuconazole. Confirm whether an order expresses drug quantity as prodrug or active moiety.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Cresemba - product and source limitations

Professional source

UCSF - isavuconazonium: dosing units and dialysis

Choose a product and source Product label GlobalRPh RX passage UCSF Infectious Diseases Management Program All evidence
Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
Qualitative no-adjustment guidance.
Source revision
Revision date not stated in the reviewed page.
Retrieved
2026-09-05 (not the revision date)

Dosing / renal protocol and limits

The regimen is expressed as isavuconazonium: 372 mg IV/orally every 8 hours for six doses, then 372 mg daily. Each 372 mg prodrug dose corresponds to 200 mg isavuconazole.

UCSF retains this schedule without renal or hemodialysis reduction. Check interactions and use antifungal-level consultation when indicated. The prodrug and active-moiety dose numbers must not be interchanged.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/isavuconazole

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

Cresemba - labeled renal guidance

Source retrieved 2026-11-07 - confirm current applicability

Qualified no-adjustment instruction; review dialysis evidence limits

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

DailyMed CRESEMBA renal-impairment statement

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

CRESEMBA isavuconazonium sulfate capsules/injection; selected renal eligibility statement, not age/weight-specific complete dosing.

Renal method: Renal-impairment categories; indexed eGFR in trial description.
Retrieved: 2026-09-07

Read local renal resultOpen this source quick answerOpen original reference
Official product label

Cresemba - labeled renal guidance

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Isavuconazonium sulfate (Cresemba), adult oral capsules or IV infusion

Renal method: Clinical renal category or population named in the cited section
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Cresemba - selected RX renal passage

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Isavuconazonium sulfate (Cresemba), adult oral capsules or IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Professional guidance

Cresemba - UCSF Infectious Diseases Management Program

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

UCSF adult oral/IV isavuconazonium sulfate dosing, 372 mg prodrug per dose.

Renal method: Institutional intermittent and continuous hemodialysis tables.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Handbook

Renal Drug Handbook, 5th edition - Isavuconazole (administered as isavuconazonium sulfate)

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Retrieved: 2026-09-05

Read local renal resultOpen this source quick answer

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Cresemba - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Handbook source

Renal Drug Handbook, 5th edition - Isavuconazole (administered as isavuconazonium sulfate)

Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.

Historical renal / replacement-therapy guidanceRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeCRESEMBA - adult prodrug dose and renal statementDailyMed CRESEMBA renal-impairment statementCresemba - labeled renal guidanceCresemba - selected RX renal passageUCSF - isavuconazonium: dosing units and dialysisCresemba - UCSF Infectious Diseases Management ProgramRenal Drug Handbook, 5th edition - Isavuconazole (administered as isavuconazonium sulfate)
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c

Product and population scope

Adult Isavuconazonium sulfate (Cresemba). Use only the product, route, indication and renal-replacement setting explicitly stated in the source protocol selected below. Sources are alternatives to compare, not ingredients of a blended regimen.

SCOPE-isavuconazonium · Source section: Editorial scope; each clinical recommendation is separately attributed belowRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

CRESEMBA - adult prodrug dose and renal statement

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.

Renal method: No renal-function dose bands specified for this summary.
Source date: DailyMed updated 2025-04-25.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

For adult invasive aspergillosis or mucormycosis, give 372 mg isavuconazonium sulfate IV or orally every 8 hours for 6 doses, then 372 mg once daily. Begin maintenance 12-24 hours after the final loading dose. Each 372-mg prodrug dose equals 200 mg isavuconazole. Infuse IV doses over at least 1 hour, never as a bolus.

No adjustment is needed for mild, moderate or severe renal impairment, including ESRD. Isavuconazole is not readily removed by dialysis. Pediatric regimens and nasogastric preparation instructions require their separate label sections; this card is adult-only.

RDM30-075-isavuconazonium-1 · Source locator: CRESEMBA - adult prodrug dose and renal statement; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c
Retrieved
2026-09-05
DailyMed Set ID
8f7f73b8-586a-4df0-935f-fecd4696c16c
Renal-function method
No renal-function dose bands specified for this summary.
Source date/version
DailyMed updated 2025-04-25.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
d76cdb8e7333a9c11a2211daf57b7cb262657b4d9b10ad3ceb177dabd9e5581d
Official

DailyMed CRESEMBA renal-impairment statement

Open original reference

Open / share this exact local source

DailyMed / Astellas Pharma US, Inc. · CRESEMBA isavuconazonium sulfate capsules/injection; selected renal eligibility statement, not age/weight-specific complete dosing.

Renal method: Renal-impairment categories; indexed eGFR in trial description.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

No dose adjustment is needed for mild, moderate or severe renal impairment, including ESRD. The clinical-trial description includes patients with eGFR below 60 mL/min/1.73 m2. This selected renal statement does not replace formulation-, age- and weight-specific dosing, interaction review or hepatic monitoring. No additional dialysis removal or post-HD supplement claim is inferred from the excerpt.

RDM43-official-isavuconazonium-f759c4c6b1-C1 · Source locator: Section 8.6 Renal Impairment.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c
Retrieved
2026-09-07
Exact label title
DailyMed CRESEMBA renal-impairment statement
DailyMed Set ID
8f7f73b8-586a-4df0-935f-fecd4696c16c
Labeler
Astellas Pharma US, Inc.
Renal-function method
Renal-impairment categories; indexed eGFR in trial description.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
68b448619408b662b19660c4f2f7e18bf52a8bf78d102c8b2f222770084a98a0
Official

Cresemba - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Isavuconazonium sulfate (Cresemba), adult oral capsules or IV infusion

Renal method: Clinical renal category or population named in the cited section
Source date: DailyMed SPL version 21, effective 2025-04-25; posted May 05, 2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Dialysis evidence: Qualified no-adjustment instruction; review dialysis evidence limits

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 and 12.3

No renal dose change is required in mild through severe impairment or ESRD. Hemodialysis does not remove isavuconazole. Confirm whether an order expresses drug quantity as prodrug or active moiety.

RDM73-cresemba-official-1 · Source locator: Renal guidance: 8.6 and 12.3

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c
Retrieved
2026-11-07
Renal-function method
Clinical renal category or population named in the cited section
Source date/version
DailyMed SPL version 21, effective 2025-04-25; posted May 05, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
d14ec691c04462130e2b0d99af14a310a3e19a487facd49c4474a2e2fbe60f2b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Cresemba - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Isavuconazonium sulfate (Cresemba), adult oral capsules or IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror includes ESRD in its no-adjustment statement and discusses lack of hemodialysis removal.

RDM73-cresemba-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cresemba-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
19a7b3554502a21d2213862b906fd5561b386afe51b8f5e4c03bd646b08617f9
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, 5th edition - Isavuconazole (administered as isavuconazonium sulfate)

Open / share this exact local source

UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.

Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date: 5th edition; 2019 copyright; historical reference
Retrieved: 2026-09-05

Historical handbook cross-check; not a current U.S. protocol

Historical renal / replacement-therapy guidance

The 20-50, 10-20 and <10 mL/min bands retain the usual indication-specific dose. PD, HD, high-flux and continuous therapy also retain usual doses; the book describes no dialytic removal. Its dose is expressed as 200 mg active isavuconazole every 8 hours for six doses then daily, beginning 12-24 hours after the final load. The U.S. CRESEMBA section expresses the equivalent as 372 mg prodrug. Do not confuse the masses.

HB30-isavuconazonium-1 · Source locator: Printed page 542: renal impairment, RRT and other information

Source-specific limits

Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 542; uploaded PDF p. 561
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source date/version
5th edition; 2019 copyright; historical reference
U.S. product identity basis
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c
Hash meaning
Local paraphrase; original book not redistributed
Local summary SHA-256
107c0b00378911a5e40d88d5cff8157934862f4561614d5b27a2a0984292bc3f
Separate professional-source layer

University and professional protocols

Professional

UCSF - isavuconazonium: dosing units and dialysis

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment guidance.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

The regimen is expressed as isavuconazonium: 372 mg IV/orally every 8 hours for six doses, then 372 mg daily. Each 372 mg prodrug dose corresponds to 200 mg isavuconazole.

UCSF retains this schedule without renal or hemodialysis reduction. Check interactions and use antifungal-level consultation when indicated. The prodrug and active-moiety dose numbers must not be interchanged.

RDM30-052-isavuconazonium-1 · Source locator: UCSF - isavuconazonium: dosing units and dialysis; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/isavuconazole
Retrieved
2026-09-05
Renal-function method
Qualitative no-adjustment guidance.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
f1469207945dd4f2c847ea79dfde9a6ce662976618a5baf051429c51971d8f2b
Professional

Cresemba - UCSF Infectious Diseases Management Program

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · UCSF adult oral/IV isavuconazonium sulfate dosing, 372 mg prodrug per dose.

Renal method: Institutional intermittent and continuous hemodialysis tables.
Source date: Online guidance checked 2026-11-07; section revision not established.
Retrieved: 2026-11-07

Professional guidance with defined scope. Publication date, institutional setting and source limitations remain controlling. This is not automatic preference over another source.

Selected renal passages reviewed; independent clinician adjudication pending.

Adult loading, maintenance and dialysis

UCSF lists 372 mg of isavuconazonium sulfate every 8 hours for six loading doses, then 372 mg daily. Its adult intermittent and continuous HD table retains that schedule. Check the prodrug versus active moiety and confirm the exact dialysis modality.

RDM73-cresemba-professional-1 · Source locator: Adult loading, maintenance and dialysis

Source identity and provenance
Source family
professional_guideline
Source
https://idmp.ucsf.edu/content/isavuconazole
Retrieved
2026-11-07
Renal-function method
Institutional intermittent and continuous hemodialysis tables.
Source date/version
Online guidance checked 2026-11-07; section revision not established.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
3ba26dfc49f4f3c6fb0016e181d09b39c04b16f2e135c97c1483c12c5f3c0755

Provenance and preservation

Additional summaries stored on this page: 3 official-label, 1 RX List, 2 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f7f73b8-586a-4df0-935f-fecd4696c16c
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
9945a7c03bd3735f620403d137b81acaaa5d3590eef2962dce9bb392dce2a85b
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top